GlaxoSmithKline Pharmaceuticals Limited
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
2/10
|
56.38 | 45.31 | 24.44% | 79.7 | -29.26% |
| P/S |
|
9.66 | 5.02 | 92.35% |
|
|
| P/BV |
|
18.71 | 6.25 | 199.21% |
|
|
| P/FCF |
|
42.82 | 170.32 | -74.86% |
|
|
| Ev/Ebitda |
|
24.13 | 13.54 | 78.19% |
|
|
| Ev/S |
|
6.34 | 4.73 | 33.88% |
|
|
| Ev/FCF |
|
39.6 | 165.19 | -76.03% |
|
|
| E/P |
|
0.025 | 0.0451 | -44.58% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
8/10
|
27.8 | 22.04 | 26.12% | 21.83 | +27.36% |
| ROE |
|
33.53 | 17.13 | 95.69% |
|
|
| ROA |
|
17.14 | 10.35 | 65.63% |
|
|
| ROIC |
|
0 | 10.89 | -100% |
|
|
| ROS |
|
17.14 | 11.8 | 45.25% |
|
|
| ROCE |
|
0 | 18.81 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
0.0172 | 1.25 | -98.63% | 0.013 | +32.19% |
| Nеt Debt/Ebitda |
|
0 | 1.05 | -100% |
|
|
| Debt/Ratio |
|
0.0044 | 0.1376 | -96.82% |
|
|
| Debt/Equity |
|
0.0042 | 0.8085 | -99.48% |
|
|
| Debt/Net Income |
|
0.0263 | 3.21 | -99.18% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
4.5/10
|
1.8 | 12.08 | -85.1% | 3.28 | -45.1% |
| Number of years of dividend growth |
|
0 | 1.26 | -100% | ||
| DSI |
|
0.8571 | 0.8404 | 1.99% |
|
|
| Average dividend growth |
|
-126.39 | -66.15 | 91.07% |
|
|
| Average percentage for 5 years |
|
3.28 | 11.32 | -71.04% |
|
|
| Average percentage for payments |
|
148.6 | 30.57 | 386.07% |
|
|
| Difference from average difference in sector |
|
-10.28 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
1/10
|
6.74 | 87.3 | -92.28% | ||
| Growth impulse Ebitda in 5 years |
|
23.53 | 45.31 | -48.07% | ||
| Growth impulse Net Income in 5 years |
|
532.97 | 138.32 | 285.32% | ||
| Growth impulse FCF in 5 years |
|
64.61 | 82.83 | -22% | ||
| Growth impulse EPS in 5 years |
|
11.29 | 288.08 | -96.08% |
IP Score
5.59/10
